Analyzing blood cell counts to improve immunochemotherapy for esophageal cancer
Trajectory Analysis of Neutrophil to Lymphocyte Ratio（NLR） and Its Association With Efficacy of Immunochemotherapy in Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
This study is testing how changes in blood cell counts can help improve immunochemotherapy treatment for patients with advanced esophageal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06125262 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the relationship between blood cell counts and the effectiveness of immunochemotherapy in patients with advanced esophageal squamous cell carcinoma. It will involve both retrospective and prospective analyses to track changes in blood cell counts from before treatment through long-term follow-up. The goal is to establish a predictive model for the efficacy and safety of immunochemotherapy based on these dynamic changes. By focusing on the trajectory of blood cell counts, the study seeks to enhance treatment outcomes for patients with this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with pathologically confirmed, potentially resectable esophageal squamous cell carcinoma who have not received prior treatment.
Not a fit: Patients with a history of thoracic surgery, other types of esophageal cancer, or severe organ dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with advanced esophageal cancer, potentially increasing their survival rates.
How similar studies have performed: While studies have shown the prognostic value of protein biomarkers in cancer treatment, this specific approach focusing on blood cell count trajectories in esophageal cancer is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed esophageal squamous cell carcinoma * Potentially resectable esophageal squamous cell carcinoma at first diagnosis (cT1-4a N1-2 M0, cT3-T4a N0M0) * Treatment-naive * Expected life span \> 6 months * Aged 18 - 75 years old * Adequate organ functions * Performance Status (PS) 0-2 * Participants are fully informed about the whole study and are willing to sign the informed consent Exclusion Criteria: * Previous history of thoracic surgery or radiation * Cervical or multi-origin esophageal cancer * Known or suspected experimental drug allergy * Pregnant or lactating women * Esophagomediastinal fistula * Peripheral neuropathy * Previous cancer history other than esophageal cancer * Severe organ function deterioration that can not tolerate neoadjuvant therapy * Previous autoimmune diseases * diabetic history \> 10 years * interstitial pulmonary disease, non-infectious pulmonitis * Active type B hepatitis * Any other conditions that may affect patients' safety and compliance
Where this trial is running
Guangzhou, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: guibin Qiao, MD — Guangdong Provincial People's Hospital
- Study coordinator: guibin Qiao, MD
- Email: guibinqiao@126.com
- Phone: 13602749153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.